In the present study, the oral administration of Pep19 successfully attenuated body-mass gain and improved the relation between circulating insulin and peripheral insulin sensitivity (disposition index) in a mice model of diet-induced obesity. Here, INS is linked to obesity due to melanocortin 4 receptor deficiency.